Sales and Marketing
Xentel
Expanding call center. New Hiring Bonus! Trades/Construction
Baker Brothers Plumbing
Dry Wallers Trades/Construction
Pioneer Landscaping
Yard Person/Loader Operator Production and Manufacturing
Pioneer Landscaping
Crushing Crew Driver/Transportation
CPC Southwest Materials
Drivers Trades/Construction
Pioneer Landscaping
Yard Person/Loader Operator Driver/Transportation
RENZENBERGER
ROAD AND YARD VAN DRIVERS

Tucson-based ImaRx Therapeutics Inc., a drug developer that went public in July, said it narrowed its second-quarter loss as revenues rose on sales of a drug that breaks up blood clots.

The company reported a net loss of $1.5 million, or 74 cents per share, in the second quarter compared with a net loss of about $4.1 or $1.62 per share in the second quarter last year.

The results include non-cash charges for accretion of preferred stock dividends totaling $434,000 in the second quarter of this year and $150,000 in the second quarter a yearr ago.

Second-quarter revenue was $2.2 million, compared with revenue of approximately $300,000 in the second quarter of 2006. The company attributed the increase to $2 million in sales of Abbokinase, a clot-busting drug ImaRx acquired last year from Abbott Laboratories.

ImaRx shares closed up 3 cents, at $3.78 per share, in trading Thursday on the Nasdaq Capital Market. The shares have closed as high as $4.80 since the company went public July 26.